Debjit Chattopadhyay
Stock Analyst at Guggenheim
(3.04)
# 1,364
Out of 4,734 analysts
74
Total ratings
44.62%
Success rate
0.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Debjit Chattopadhyay
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| QURE uniQure | Reiterates: Buy | n/a | $14.91 | - | 5 | Dec 11, 2024 | |
| PRME Prime Medicine | Reiterates: Buy | $18 | $2.91 | +518.56% | 3 | Dec 3, 2024 | |
| BNTC Benitec Biopharma | Reiterates: Buy | $17 | $10.77 | +57.85% | 2 | Dec 3, 2024 | |
| CNTA Centessa Pharmaceuticals | Maintains: Buy | $24 → $28 | $16.46 | +70.11% | 4 | Nov 15, 2024 | |
| FOLD Amicus Therapeutics | Maintains: Buy | $13 → $15 | $9.51 | +57.73% | 2 | Nov 7, 2024 | |
| IONS Ionis Pharmaceuticals | Maintains: Buy | $70 → $65 | $32.68 | +98.90% | 3 | Oct 9, 2024 | |
| RZLT Rezolute | Initiates: Buy | $11 | $4.92 | +123.58% | 1 | Aug 27, 2024 | |
| DYN Dyne Therapeutics | Maintains: Buy | $45 → $50 | $14.55 | +243.64% | 3 | Aug 15, 2024 | |
| VRTX Vertex Pharmaceuticals | Maintains: Buy | $450 → $558 | $427.89 | +30.41% | 7 | Aug 2, 2024 | |
| CRSP CRISPR Therapeutics AG | Assumes: Neutral | n/a | $41.51 | - | 1 | Jun 28, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $19 | $4.56 | +316.67% | 2 | Apr 30, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $22 | $5.22 | +321.46% | 1 | Mar 26, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $130 → $175 | $151.55 | +15.47% | 3 | Feb 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $30 | $23.70 | +26.58% | 1 | Jan 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $40 | $49.17 | -18.65% | 1 | Nov 21, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Reiterates: Buy | $110 | $62.53 | +75.92% | 3 | Sep 13, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $43 → $29 | $1.84 | +1,476.09% | 1 | Nov 21, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $13 → $11 | $0.62 | +1,682.82% | 2 | Nov 11, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $50 | $41.28 | +21.12% | 2 | Oct 13, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $264.99 | - | 1 | Jun 27, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $130 | $24.53 | +429.96% | 1 | Jan 5, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $28 | $1.53 | +1,730.07% | 1 | Dec 16, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $170 | $9.94 | +1,610.26% | 1 | Oct 5, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Assumes: Buy | $20 | $11.10 | +80.18% | 2 | Dec 15, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $260 → $221 | $116.79 | +89.23% | 4 | Aug 31, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $270 → $123 | $23.83 | +416.16% | 8 | Aug 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $60 → $54 | $14.29 | +277.89% | 3 | Jul 9, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $60 | $2.57 | +2,234.63% | 3 | Dec 3, 2019 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | n/a | $33.23 | - | 3 | Jun 26, 2017 |
uniQure
Dec 11, 2024
Reiterates: Buy
Price Target: n/a
Current: $14.91
Upside: -
Prime Medicine
Dec 3, 2024
Reiterates: Buy
Price Target: $18
Current: $2.91
Upside: +518.56%
Benitec Biopharma
Dec 3, 2024
Reiterates: Buy
Price Target: $17
Current: $10.77
Upside: +57.85%
Centessa Pharmaceuticals
Nov 15, 2024
Maintains: Buy
Price Target: $24 → $28
Current: $16.46
Upside: +70.11%
Amicus Therapeutics
Nov 7, 2024
Maintains: Buy
Price Target: $13 → $15
Current: $9.51
Upside: +57.73%
Ionis Pharmaceuticals
Oct 9, 2024
Maintains: Buy
Price Target: $70 → $65
Current: $32.68
Upside: +98.90%
Rezolute
Aug 27, 2024
Initiates: Buy
Price Target: $11
Current: $4.92
Upside: +123.58%
Dyne Therapeutics
Aug 15, 2024
Maintains: Buy
Price Target: $45 → $50
Current: $14.55
Upside: +243.64%
Vertex Pharmaceuticals
Aug 2, 2024
Maintains: Buy
Price Target: $450 → $558
Current: $427.89
Upside: +30.41%
CRISPR Therapeutics AG
Jun 28, 2024
Assumes: Neutral
Price Target: n/a
Current: $41.51
Upside: -
Apr 30, 2024
Initiates: Buy
Price Target: $19
Current: $4.56
Upside: +316.67%
Mar 26, 2024
Initiates: Buy
Price Target: $22
Current: $5.22
Upside: +321.46%
Feb 27, 2024
Maintains: Buy
Price Target: $130 → $175
Current: $151.55
Upside: +15.47%
Jan 18, 2024
Initiates: Buy
Price Target: $30
Current: $23.70
Upside: +26.58%
Nov 21, 2023
Assumes: Buy
Price Target: $40
Current: $49.17
Upside: -18.65%
Sep 13, 2023
Reiterates: Buy
Price Target: $110
Current: $62.53
Upside: +75.92%
Nov 21, 2022
Maintains: Buy
Price Target: $43 → $29
Current: $1.84
Upside: +1,476.09%
Nov 11, 2022
Maintains: Buy
Price Target: $13 → $11
Current: $0.62
Upside: +1,682.82%
Oct 13, 2022
Upgrades: Buy
Price Target: $50
Current: $41.28
Upside: +21.12%
Jun 27, 2022
Downgrades: Neutral
Price Target: n/a
Current: $264.99
Upside: -
Jan 5, 2022
Initiates: Buy
Price Target: $130
Current: $24.53
Upside: +429.96%
Dec 16, 2021
Initiates: Buy
Price Target: $28
Current: $1.53
Upside: +1,730.07%
Oct 5, 2021
Initiates: Buy
Price Target: $170
Current: $9.94
Upside: +1,610.26%
Dec 15, 2020
Assumes: Buy
Price Target: $20
Current: $11.10
Upside: +80.18%
Aug 31, 2020
Maintains: Buy
Price Target: $260 → $221
Current: $116.79
Upside: +89.23%
Aug 24, 2020
Downgrades: Neutral
Price Target: $270 → $123
Current: $23.83
Upside: +416.16%
Jul 9, 2020
Maintains: Buy
Price Target: $60 → $54
Current: $14.29
Upside: +277.89%
Dec 3, 2019
Downgrades: Neutral
Price Target: $60
Current: $2.57
Upside: +2,234.63%
Jun 26, 2017
Downgrades: Neutral
Price Target: n/a
Current: $33.23
Upside: -